CF
KRYS icon

Corebridge Financial’s Krystal Biotech KRYS Stock Holding History

Corebridge Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12,970
Closed -$2.34M – 1470
2025
Q1 		$2.34M Sell
12,970
-255
-2% -$42.9K 0.01% 927
2024
Q4 		$2.07M Sell
13,225
-1,032
-7% -$183K 0.01% 1004
2024
Q3 		$2.6M Sell
14,257
-133
-0.9% -$25.6K 0.01% 943
2024
Q2 		$2.64M Buy
+14,390
New +$2.42M 0.01% 918

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Corebridge Financial's KRYS Position: Q2 2025 in Review

Corebridge Financial sold out of Krystal Biotech (KRYS) in Q2 2025, closing a stake of 12,970 shares — an estimated $2.34M sold.

Corebridge Financial first reported a position in KRYS in Q2 2024 and held it in 4 quarters. The position peaked at $2.64M in Q2 2024. 275 funds tracked by Wall St. Rank hold KRYS as of Q2 2025.

  • Corebridge Financial reported no remaining Krystal Biotech position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 12,970 Krystal Biotech shares in Q2 2025, an estimated $2.34M.
  • Corebridge Financial first reported a position in Krystal Biotech in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Krystal Biotech position peaked at $2.64M in Q2 2024.
  • 275 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.